BR0111956A - Tratamento do vìrus do papiloma humano - Google Patents

Tratamento do vìrus do papiloma humano

Info

Publication number
BR0111956A
BR0111956A BR0111956-7A BR0111956A BR0111956A BR 0111956 A BR0111956 A BR 0111956A BR 0111956 A BR0111956 A BR 0111956A BR 0111956 A BR0111956 A BR 0111956A
Authority
BR
Brazil
Prior art keywords
papilloma virus
human papilloma
patient
type
human
Prior art date
Application number
BR0111956-7A
Other languages
English (en)
Portuguese (pt)
Inventor
John Neefe
Stephen Goldstone
Mark Winnett
Marvin Siegel
Original Assignee
Stressgen Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stressgen Biotechnologies Corp filed Critical Stressgen Biotechnologies Corp
Publication of BR0111956A publication Critical patent/BR0111956A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Compounds Of Unknown Constitution (AREA)
BR0111956-7A 2000-06-26 2001-06-26 Tratamento do vìrus do papiloma humano BR0111956A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21420200P 2000-06-26 2000-06-26
PCT/US2001/020240 WO2002000242A2 (en) 2000-06-26 2001-06-26 Human papilloma virus treatment

Publications (1)

Publication Number Publication Date
BR0111956A true BR0111956A (pt) 2003-05-13

Family

ID=22798190

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111956-7A BR0111956A (pt) 2000-06-26 2001-06-26 Tratamento do vìrus do papiloma humano

Country Status (27)

Country Link
US (4) US20020110566A1 (enExample)
EP (1) EP1296711B1 (enExample)
JP (1) JP2004512264A (enExample)
KR (2) KR20080075560A (enExample)
CN (1) CN100441223C (enExample)
AT (1) ATE326236T1 (enExample)
AU (3) AU2001271449B2 (enExample)
BR (1) BR0111956A (enExample)
CA (1) CA2413543A1 (enExample)
CY (1) CY1105389T1 (enExample)
CZ (1) CZ20024154A3 (enExample)
DE (1) DE60119734T2 (enExample)
DK (1) DK1296711T3 (enExample)
EE (1) EE200200709A (enExample)
ES (1) ES2263637T3 (enExample)
HR (1) HRP20021015A2 (enExample)
HU (1) HUP0301308A3 (enExample)
IL (1) IL153474A0 (enExample)
MX (1) MXPA02012858A (enExample)
NO (1) NO20026044L (enExample)
NZ (1) NZ523408A (enExample)
PL (1) PL359930A1 (enExample)
PT (1) PT1296711E (enExample)
RU (1) RU2282461C2 (enExample)
SK (1) SK18362002A3 (enExample)
WO (1) WO2002000242A2 (enExample)
ZA (1) ZA200210211B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US6495347B1 (en) 1999-07-08 2002-12-17 Stressgen Biotechnologies Corporation Induction of a Th1-like response in vitro
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
IL153474A0 (en) * 2000-06-26 2003-07-06 Stressgen Biotechnologies Corp Human papilloma virus treatment
AU2001278117A1 (en) 2000-08-03 2002-02-18 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
US20080044435A1 (en) * 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
CN1264572C (zh) 2001-02-05 2006-07-19 斯特雷斯根生物技术公司 治疗hbv的融合蛋白及其应用
US6649402B2 (en) * 2001-06-22 2003-11-18 Wisconsin Alumni Research Foundation Microfabricated microbial growth assay method and apparatus
JP2006503914A (ja) * 2002-10-21 2006-02-02 エムジーアイ ファーマ バイオロジックス インコーポレイテッド ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法
AU2003293942B2 (en) * 2002-12-20 2009-12-10 Glaxosmithkline Biologicals Sa HPV-16 and -18 L1 VLP vaccine
EP1644048B1 (en) 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
CA2526720C (en) 2003-05-22 2013-10-22 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US7285386B2 (en) * 2003-10-29 2007-10-23 University Of New Mexico, And Educational Institution Of The State Of New Mexico RhPV as a model for HPV-induced cancers
DE10357677A1 (de) * 2003-12-10 2005-07-14 Greiner Bio-One Gmbh Primer und Sonden zum Nachweis genitaler HPV-Genotypen
US20050208482A1 (en) * 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
AU2005322960A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
RU2285537C1 (ru) * 2005-04-05 2006-10-20 Автономная некоммерческая организация "Институт молекулярной диагностики (АНО "ИнМоДи") Противоопухолевый пептидный препарат на основе фрагмента альфа-фетопротеина, его конъюгат, фармацевтическая композиция и способ лечения гормонзависимых опухолей
RU2283128C1 (ru) * 2005-04-05 2006-09-10 Сергей Викторович Луценко Способ получения препарата белка из семейства стрессовых и препарат белка hsp70, полученный этим способом
ATE506063T1 (de) * 2005-04-27 2011-05-15 Univ Leiden Medical Ct Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien
RU2290204C1 (ru) * 2005-07-27 2006-12-27 Общество с ограниченной ответственностью "Аванген" Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани
CN101378781B (zh) * 2005-08-03 2013-08-07 美国弗劳恩霍夫股份有限公司 制造免疫球蛋白的组合物和方法
US7622121B2 (en) * 2005-09-21 2009-11-24 New York University Heat shock proteins from Mycobacterium leprae and uses thereof
AU2007215080A1 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
US8277816B2 (en) * 2006-02-13 2012-10-02 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
JP2009526780A (ja) * 2006-02-13 2009-07-23 フラウンホーファー ユーエスエー， インコーポレイテッド Ｈｐｖ抗原、ワクチン組成物、および関連する方法
RU2316342C1 (ru) * 2006-03-31 2008-02-10 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Вакцинная композиция для профилактики и лечения онкологических заболеваний, рекомбинантная плазмидная днк, обеспечивающая синтез гибридного белка, способ его получения
JP2009538836A (ja) * 2006-05-31 2009-11-12 ヌベンタ バイオファーマシューティカルズ コーポレイション 生物活性の精製ＨｓｐＥ７組成物
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
WO2008124483A1 (en) * 2007-04-04 2008-10-16 Specigen, Inc. Protein cage immunotherapeutics
US8778348B2 (en) * 2007-04-28 2014-07-15 Ibio Inc. Trypanosoma antigens, vaccine compositions, and related methods
EP2178558B1 (en) * 2007-07-11 2014-04-30 iBio, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
CA2696764A1 (en) * 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
US20090117140A1 (en) * 2007-09-26 2009-05-07 Mayumi Nakagawa Human papilloma virus dominant CD4 T cell epitopes and uses thereof
WO2009094006A2 (en) * 2007-10-25 2009-07-30 Wake Forest University Health Sciences Bordetella outer-membrane protein antigens and methods of making and using the same
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
WO2009117116A2 (en) 2008-03-20 2009-09-24 University Of Miami Heat shock protein gp96 vaccination and methods of using same
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
US20110195966A1 (en) * 2008-10-31 2011-08-11 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
HUE031367T2 (en) * 2008-11-28 2017-07-28 Novartis Ag A pharmaceutical combination comprising an Hsp 90 inhibitor and a mTOR inhibitor
BRPI1009215B1 (pt) 2009-03-23 2019-10-29 Nanirx Inc composição farmacêutica compreendendo uma sequência de aminoácidos modificada da proteína trans-ativadora de transcrição (tat) do vírus da imunodeficiência humana (hiv) e uso de um polipeptídeo derivado de tat para tratar câncer
CA2776144C (en) 2009-09-29 2020-10-27 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
US9662510B2 (en) 2010-07-19 2017-05-30 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
RU2438652C1 (ru) * 2010-12-10 2012-01-10 Закрытое Акционерное Общество "Велес Фарма" Средство для лечения заболеваний шейки матки, ассоциированных с вирусом папилломы человека, в виде вагинального раствора для орошения, набор и способ его получения
RU2438703C1 (ru) * 2010-12-10 2012-01-10 Закрытое Акционерное Общество "Велес Фарма" Средство для лечения заболеваний шейки матки, ассоциированных с вирусом папилломы человека, в виде вагинального суппозитория
RU2438702C1 (ru) * 2010-12-10 2012-01-10 Закрытое Акционерное Общество "Велес Фарма" Средство для лечения заболеваний шейки матки, ассоциированных с вирусом папилломы человека, в виде вагинальных капсул
US20140286991A1 (en) * 2011-02-23 2014-09-25 University Of Miami Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv
US9028884B2 (en) 2013-08-13 2015-05-12 Preventamedics LLC Medical delivery devices and methods for applying a barrier composition to a targeted skin surface
EP3052127A1 (en) 2013-10-04 2016-08-10 PIN Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
GB2541749B (en) 2015-08-31 2020-12-09 Emblation Ltd An interference suppression apparatus and method
US11497926B2 (en) 2016-08-08 2022-11-15 Emblation Limited Method and apparatus for the treatment, management and/or control of pain
CA3058380A1 (en) 2017-03-28 2018-10-04 Emblation Limited Stenosis treatment
EP3606550A2 (en) * 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
CN108409866A (zh) * 2018-01-23 2018-08-17 合肥瑞城生生物科技有限公司 一种用于治疗和预防人乳头瘤病毒感染及相关疾病的多表位组合肽
MX2021001502A (es) 2018-08-06 2021-07-15 Nielsen Biosciences Inc Tratamiento de verrugas.
CN114478712B (zh) * 2022-03-29 2022-09-23 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666847A (en) * 1981-01-16 1987-05-19 Collaborative Research, Inc. Recombinant DNA means and method
NO172595C (no) 1983-02-07 1993-08-11 Battelle Memorial Institute Fremgangsmaate og ekspresjonsplasmid for fremstilling av hemagglutinin under kontroll av drosophila hsp-promoter
US4797359A (en) * 1983-05-10 1989-01-10 Board Of Regents, The University Of Texas System Heat shock regulated production of selected and fused proteins in yeast
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4784941A (en) * 1985-04-08 1988-11-15 Genetic Systems Corporation Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
JPS62164696A (ja) 1986-01-06 1987-07-21 エフ．ホフマン　―　ラ　ロシュ　アーゲー ＨＴＬＶ−３ｇａｇ遺伝子の発現
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4906742A (en) 1986-07-31 1990-03-06 Whitehead Institute For Biomedical Research Encoding antigens of M. Leprae
US6007806A (en) 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
NL8701163A (nl) 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
AU1548388A (en) 1987-02-02 1988-08-24 Whitehead Institute For Biomedical Research Mycobacterium tuberculosis genes and encoding protein antigens
US4952395A (en) 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
US5256767A (en) * 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
NL8703107A (nl) 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5204259A (en) * 1988-05-06 1993-04-20 Pharmacia Genetic Engineering, Inc. Methods and systems for producing HIV antigens
WO1989012455A1 (en) 1988-06-15 1989-12-28 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
WO1990010230A1 (en) 1989-02-23 1990-09-07 University Of Ottawa Polypeptide having immunological activity for use as diagnostic reagent and/or vaccine
US5114844A (en) 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
JPH04506297A (ja) 1989-06-19 1992-11-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ ベクター媒介ゲノム挿入及びｂｃｇにおけるｄｎａの発現
GB8919321D0 (en) 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
EP0556248B1 (en) 1990-11-08 1997-06-25 University College London Mycobacterium as adjuvant for antigens
GB2251186A (en) 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
EP0521220A1 (en) 1991-06-14 1993-01-07 Institut Pasteur Recombinant immunogenic actinomycetale
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5580563A (en) 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
GB9211736D0 (en) 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
US5736146A (en) 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
EP1221488A1 (en) 1993-06-04 2002-07-10 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US5404142A (en) 1993-08-05 1995-04-04 Analog Devices, Incorporated Data-directed scrambler for multi-bit noise shaping D/A converters
JPH09504000A (ja) * 1993-08-11 1997-04-22 ジェナー テクノロジーズ 前立腺癌ワクチン
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
IL109790A0 (en) 1994-05-25 1994-08-26 Yeda Res & Dev Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
GB9419979D0 (en) 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
US5955087A (en) 1995-02-24 1999-09-21 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
EP0851764A4 (en) 1995-08-18 2002-08-07 Sloan Kettering Inst Cancer VACCINE BASED ON HEAT SHOCK PROTEINS AND IMMUNOTHERAPIES
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
WO1997026910A2 (de) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
IL128269A0 (en) * 1996-07-29 1999-11-30 Cantab Pharmaceuticals Res Ltd Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
ES2258796T3 (es) 1996-11-26 2006-09-01 Stressgen Biotechnologies Corporation Proteinas de fusion que contienen proteinas de estres para inducir respuestas inmunitarias.
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
CA2282426A1 (en) 1997-02-18 1998-08-20 The Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
DK1002110T3 (da) * 1997-08-05 2003-05-26 Stressgen Biotechnologies Corp Immunsvar mod HPV-antigener fremkaldt af sammensætninger, som omfatter et HPV-antigen og et stressprotein eller en ekspressionsvektor i stand til at ekspressere disse proteiner
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
CN1248631A (zh) * 1998-09-24 2000-03-29 周国庆 一种免疫预防和免疫治疗性病和癌症的融合蛋白
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US6497880B1 (en) * 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
US6495347B1 (en) * 1999-07-08 2002-12-17 Stressgen Biotechnologies Corporation Induction of a Th1-like response in vitro
CA2383213A1 (en) 1999-09-10 2001-03-15 Fordham University Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
US20010034042A1 (en) 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
WO2001052890A1 (en) 2000-01-21 2001-07-26 University Of Connecticut Health Center Heat shock/stress protein complexes as vaccines against neurodegenerative disorders
AU2001229592A1 (en) 2000-01-21 2001-07-31 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
AU2001229597A1 (en) 2000-01-21 2001-07-31 University Of Connecticut Health Center Compositions and methods to treat neurodegenerative disorders
IL153474A0 (en) * 2000-06-26 2003-07-06 Stressgen Biotechnologies Corp Human papilloma virus treatment

Also Published As

Publication number Publication date
US20080063661A1 (en) 2008-03-13
US20020110566A1 (en) 2002-08-15
CY1105389T1 (el) 2010-04-28
HRP20021015A2 (en) 2004-02-29
DE60119734T2 (de) 2007-04-26
AU2006203436A1 (en) 2006-08-31
DE60119734D1 (de) 2006-06-22
MXPA02012858A (es) 2004-04-20
RU2282461C2 (ru) 2006-08-27
WO2002000242A2 (en) 2002-01-03
KR100919266B1 (ko) 2009-09-30
EE200200709A (et) 2004-08-16
HUP0301308A2 (hu) 2003-08-28
ZA200210211B (en) 2004-03-17
IL153474A0 (en) 2003-07-06
EP1296711A2 (en) 2003-04-02
PL359930A1 (en) 2004-09-06
CZ20024154A3 (cs) 2003-08-13
NO20026044D0 (no) 2002-12-16
KR20030025939A (ko) 2003-03-29
PT1296711E (pt) 2006-08-31
AU2001271449B2 (en) 2006-08-24
NZ523408A (en) 2006-02-24
US20030170268A1 (en) 2003-09-11
CA2413543A1 (en) 2002-01-03
CN1678344A (zh) 2005-10-05
HUP0301308A3 (en) 2010-01-28
US6797491B2 (en) 2004-09-28
US20040235741A1 (en) 2004-11-25
US7211411B2 (en) 2007-05-01
US7754449B2 (en) 2010-07-13
JP2004512264A (ja) 2004-04-22
CN100441223C (zh) 2008-12-10
ES2263637T3 (es) 2006-12-16
KR20080075560A (ko) 2008-08-18
EP1296711B1 (en) 2006-05-17
NO20026044L (no) 2003-02-20
ATE326236T1 (de) 2006-06-15
DK1296711T3 (da) 2006-08-28
SK18362002A3 (sk) 2004-02-03
WO2002000242A3 (en) 2002-10-03
AU7144901A (en) 2002-01-08
WO2002000242A8 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
BR0111956A (pt) Tratamento do vìrus do papiloma humano
BR0308444A (pt) Composição de vacina, método de produção de vacina, uso de uma mistura de vlps de hpv 16, hpv 18, hvp 31 e hpv 45, método de prevenção da infecção por hpv ou tratamento de doença relacionada com a infecção por hpv
BR0014155A (pt) Prevenção da miocardite, do aborto e da infecção intrauterina, associados com o circovìrus-2 porcino
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
BR0316291A (pt) Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv
PL352201A1 (en) Porcine circovirus vaccine in recombinant poxvirus
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
DE69837934D1 (de) Multisystemisches kümmerwuchssyndrom durch viren in schweine
DE60142776D1 (de) Behandlung von herpes infektion mit anwendung von immunomodulatore polynukleotide sequenzen
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
EP1305042A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SLEW-TONE INFECTIONS
BR0206995A (pt) Tratamento do vìrus da hepatite b
AP9801286A0 (en) Therapeutic compounds.
FR2870126A1 (fr) Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
BRPI0413684A (pt) compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos
MY124071A (en) Treatment of viral disease in swine
ITMI913493A1 (it) Dispositivo per la disinfezione o la immunizzazione di zone del corpo umano esposte al contagio, da germi, batteri e virus
WO2002006343A3 (en) Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau
BR9908540A (pt) Molécula de ácido nucleico recombinante, célula hospedeira recombinante, composição farmacêutica, e, processo para induzir uma resposta imune contra vìrus de hepatite c em um humano não infectado por vìrus de hepatite c, para imunizar um humano suscetìvel a vìrus de hepatite c, e para tratar um humano que é infectado com vìrus de hepatite c
ATE313628T1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
PT1150981E (pt) Composto nucleosidico terapeutico
EA199700353A1 (ru) Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции
RU95108616A (ru) Способ лечения верхней ретро- или микрогнатии, осложненной расщелиной твердого неба и альвеолярного отростка

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NVENTA BIOPHARMACEUTICALS CORPORATION (CA)

Free format text: ALTERADO DE: STRESSGEN BIOTECHNOLOGIES CORP.

B25G Requested change of headquarter approved

Owner name: NVENTA BIOPHARMACEUTICALS CORPORATION (CA)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070139841/RJ DE 03/10/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A E 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2206 DE 16/04/2013.